
Global & Norway Cancer Therapeutics Market to 2031
Description
Norway's universal, publicly funded healthcare system ensures equitable access to cancer treatment for all residents. The Norwegian government has consistently prioritized cancer research, with a focus on developing novel therapies and improving early detection techniques. In 2023, the Norwegian Cancer Society allocated approximately US$ 6.67 million (NOK 71 million) to researchers at the Faculty of Medicine (MED), highlighting its commitment to advancing cancer research in the country.
Further reinforcing these efforts, in November 2024, two significant MATRIX projects received a combined funding of around US$ 19.01 million (NOK 210 million) from the Norwegian Cancer Society. These include MATRIX-RARE, a national clinical trial and research initiative, and another project aimed at inhibiting regulatory T cells to help restore the body’s immune response against cancer.
These substantial investments reflect Norway’s strategic approach to fostering innovation in cancer care. By supporting cutting-edge research and therapeutic development, the country is playing a pivotal role in the ongoing expansion of the cancer therapeutics market.
Further reinforcing these efforts, in November 2024, two significant MATRIX projects received a combined funding of around US$ 19.01 million (NOK 210 million) from the Norwegian Cancer Society. These include MATRIX-RARE, a national clinical trial and research initiative, and another project aimed at inhibiting regulatory T cells to help restore the body’s immune response against cancer.
These substantial investments reflect Norway’s strategic approach to fostering innovation in cancer care. By supporting cutting-edge research and therapeutic development, the country is playing a pivotal role in the ongoing expansion of the cancer therapeutics market.
Table of Contents
100 Pages
- 1. Introduction
- 1.1 Report Guidance
- 1.2 Market Segmentation
- 2. Executive Summary
- 2.1 Key Insights
- 3. Research Methodology
- 3.1 Secondary Research
- 3.2 Primary Research
- 3.2.1 Data Triangulation and Validation:
- 4. Norway Cancer Therapeutics Market Landscape
- 4.1 Overview
- 4.2 Ecosystem Analysis
- 4.2.1 List of Vendors in the Value Chain
- 5. Cancer Therapeutics Market Key Market Dynamics
- 5.1 Cancer Therapeutics Market – Key Market Dynamics
- 5.2 Market Drivers
- 5.3 Market Restraints
- 5.4 Market Opportunities
- 5.5 Future Trends
- 5.6 Impact of Drivers and Restraints
- 6. Norway Cancer Therapeutics Market – Analysis
- 6.1 Norway Cancer Therapeutics Market Revenue (US$ Million), 2021–2031
- 6.2 Norway Cancer Therapeutics Market Revenue and Forecast Analysis
- 7. Norway Cancer Therapeutics Market Analysis – by Therapy Types
- 7.1 Norway Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Therapy Types
- 8. Norway Cancer Therapeutics Market Analysis – by Indications
- 8.1 Norway Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Indications
- 9. Norway Cancer Therapeutics Market Analysis – by Distribution Channel
- 9.1 Norway Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Distribution Channel
- 10. Competitive Landscape
- 10.1 Heat Map Analysis by Key Players
- 10.1 Company Positioning and Concentration
- 11. Industry Landscape
- 11.1 Overview
- 11.2 Market Initiative
- 11.2 Partnerships and Collaborations
- 11.2 Other Developments
- 12. Company Profiles
- 12.1 Bristol-Myers Squibb Co
- 12.1. 1 Key Facts
- 12.1. 2 Business Description
- 12.1. 3 Products and Services
- 12.1. 4 Financial Overview
- 12.1. 5 SWOT Analysis
- 12.1. 6 Key Developments
- 12.2 AbbVie Inc
- 12.2. 1 Key Facts
- 12.2. 2 Business Description
- 12.2. 3 Products and Services
- 12.2. 4 Financial Overview
- 12.2. 5 SWOT Analysis
- 12.2. 6 Key Developments
- 12.3 Johnson & Johnson
- 12.3. 1 Key Facts
- 12.3. 2 Business Description
- 12.3. 3 Products and Services
- 12.3. 4 Financial Overview
- 12.3. 5 SWOT Analysis
- 12.3. 6 Key Developments
- 12.4 F. Hoffmann-La Roche Ltd
- 12.4. 1 Key Facts
- 12.4. 2 Business Description
- 12.4. 3 Products and Services
- 12.4. 4 Financial Overview
- 12.4. 5 SWOT Analysis
- 12.4. 6 Key Developments
- 12.5 Pfizer Inc
- 12.5. 1 Key Facts
- 12.5. 2 Business Description
- 12.5. 3 Products and Services
- 12.5. 4 Financial Overview
- 12.5. 5 SWOT Analysis
- 12.5. 6 Key Developments
- 12.6 AstraZeneca Plc
- 12.6. 1 Key Facts
- 12.6. 2 Business Description
- 12.6. 3 Products and Services
- 12.6. 4 Financial Overview
- 12.6. 5 SWOT Analysis
- 12.6. 6 Key Developments
- 12.7 Merck KGaA
- 12.7. 1 Key Facts
- 12.7. 2 Business Description
- 12.7. 3 Products and Services
- 12.7. 4 Financial Overview
- 12.7. 5 SWOT Analysis
- 12.7. 6 Key Developments
- 12.8 Novartis AG
- 12.8. 1 Key Facts
- 12.8. 2 Business Description
- 12.8. 3 Products and Services
- 12.8. 4 Financial Overview
- 12.8. 5 SWOT Analysis
- 12.8. 6 Key Developments
- 12.9 Astellas Pharma Inc
- 12.9. 1 Key Facts
- 12.9. 2 Business Description
- 12.9. 3 Products and Services
- 12.9. 4 Financial Overview
- 12.9. 5 SWOT Analysis
- 12.9. 6 Key Developments
- 12.10 Eli Lilly and Co
- 12.10. 1 Key Facts
- 12.10. 2 Business Description
- 12.10. 3 Products and Services
- 12.10. 4 Financial Overview
- 12.10. 5 SWOT Analysis
- 12.10. 6 Key Developments
- 13. Appendix
- 13.1 About Business Market Insights
- 13.2 List of Abbreviations
- TABLE OF TABLES
- Table 1. Norway Cancer Therapeutics Market Segmentation
- Table 2. List of Vendors
- Table 3. Norway Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million)
- Table 4. Norway Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million)
- Table 5. Norway Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Therapy Types
- Table 6. Norway Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Therapy Types
- Table 7. Norway Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Indications
- Table 8. Norway Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Indications
- Table 9. Norway Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Distribution Channel
- Table 10. Norway Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Distribution Channel
- Table 11. List of Abbreviations
- TABLE OF FIGURES
- Figure 1. Impact Analysis of Drivers and Restraints
- Figure 2. Norway Cancer Therapeutics Market Revenue, (US$ Million), 2021–2031
- Figure 3. Heat Map Analysis by Key Players
- Figure 4. Company Positioning and Concentration
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.